Real-life cohort experience after implementing HIV pre-exposure prophylaxis for one year in northwest Spain.

Methods: A retrospective cohort study was undertaken in the Alvaro-Cunqueiro Hospital, Vigo which included every individual who started daily emtricitabine/tenofovir-disoproxil-fumarate (FTC/TDF) between November-2019 and October-2021. Clinical and epidemiological data were obtained from the patient's medical records. The effectiveness and safety of FTC/TDF were assessed by HIV serology and renal function monitoring every 3 months. Anal, urethral, and oropharyngeal exudates were collected quarterly after the baseline visit.

Results: = 0.013). Among the study population included in the anal screening programme, the frequency of dysplasia was 9%.

Conclusion: = 0.013). Among the study population included in the anal screening programme, the frequency of dysplasia was 9%.